ClinicalTrials.gg
RecruitingNCT05962346FETOUpdated Mar 19, 2026

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

An interventional study of BALT GOLDBALL 2 detachable latex ballon and BALTACCIBDPE100 Microcatheter in Congenital Diaphragmatic Hernia, sponsored by Mauro H. Schenone. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Mauro H. Schenone · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Planned enrollment
20th of 36
20 · median 21
Started
2026
with 4 others
No phase
28 of 45
18 open now
Primary completion
2043-07
later than 27 of 27 live
Registered
34th of 45
by date

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 20th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2026, is one of 28 with no phase, reaches primary completion later than 27 of the 27 other live ones, and was the 34th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe congenital diaphragmatic hernia (CDH).

03

Conditions studied

  • Congenital Diaphragmatic Hernia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton pregnancy
  • Normal fetal karyotype or microarray. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks
  • Isolated severe left CDH with O/E LHR \< 25% )
  • Gestation age at enrollment prior to 29 wks plus 6 days.
  • Pulmonary hypoplasia with ultrasound O/E LHR \< 25% (measured at 18 0/7 to 29 5/7 weeks) at the time of surgery.
  • Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound
  • Patient meets psychosocial criteria: able to reside within 30 minutes of Mayo Clinic, Rochester and able to comply with the travel for the follow-up requirements of the trial; patient has a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic
  • Patient is willing and able to give
  • Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT)

Exclusion criteria

Exclusion Criteria:

  • Multi-fetal pregnancy
  • History of natural rubber latex allergy
  • Preterm labor, cervix shortened (\<20 mm) at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor
  • Psychosocial ineligibility, precluding consent: inability to reside within 30 minutes of Mayo Clinic, Rochester and inability to comply with the travel for the follow-up requirements of the trial; patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic
  • Right sided CDH or bilateral CDH, isolated left sided with O/E LHR >25% measured at 18 0/7 to 29 6/7 weeks) as determined by ultrasound
  • Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram that will significantly worsen prognosis. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring
  • Maternal to fetoscopic surgery
  • History of incompetent cervix with or without cerclage
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  • Maternal , Hepatitis-B, Hepatitis-C status positive.
  • Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality that will make the procedure technically unfeasible
  • No safe or technically feasible fetoscopic approach to balloon placement
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    FETO Group

    Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.

    Device: BALT GOLDBALL 2 detachable latex ballon · Device: BALTACCIBDPE100 Microcatheter · Device: Storz fetoscopic operating sheath and miniature telescope/fetoscope

Interventions

  • DeviceBALT GOLDBALL 2 detachable latex ballon

    Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.

  • DeviceBALTACCIBDPE100 Microcatheter

    Used to deliver the detachable balloon

  • DeviceStorz fetoscopic operating sheath and miniature telescope/fetoscope

    Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.

06

What researchers measure

Primary outcomes

  1. Technical success of the balloon placement procedure

    The number of successful balloon placement procedures defined as balloon was correctly inflated and placed/secured in the trachea.

    Time frame: Up to 29 weeks gestation

  2. Technical success of balloon retrieval procedure

    The number of successful balloon retrieval procedure defined as antenatal removal of the balloon.

    Time frame: Up to 34 weeks gestation

  3. Operative times

    FETO placement and release operative times reported in minutes

    Time frame: Up to 34 weeks gestation

  4. Frequency of unplanned balloon removal

    The frequency of non-emergent and emergent completion of FETO release (unplanned balloon removal)

    Time frame: Up to 34 weeks gestation

  5. Number of incidences of maternal complications

    Maternal complications including preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis

    Time frame: Up to 41 weeks gestation

  6. Gestational Age at Delivery

    Gestation Age reported at time of delivery

    Time frame: Up to 41 weeks gestation

Secondary outcomes

  1. Fetal Lung Growth as measured via Fetal Lung Volume

    Fetal Lung Volume as measured via ultrasound

    Time frame: Up to 24 months post partum

  2. Fetal Lung Growth as measured via LHR

    Lung area to head circumference Ratio (LHR) as measured via ultrasound

    Time frame: Up to 24 months post partum

  3. Fetal Survival

    Survival at 30 days, discharge from the hospital and at 6 months if still hospitalized

    Time frame: Up to 6 months post partum

  4. Fetal Oxygen Dependency

    Oxygen dependency graded as none, mild, moderate, severe as assessed by treating physician

    Time frame: Up to 24 months post partum

  5. Occurrence of severe pulmonary hypertension

    Number of occurrence of severe pulmonary hypertension in infants based on echocardiogram

    Time frame: Up to 24 months post partum

  6. ECMO Support

    Number of infants reported that required Extracorporeal membrane oxygenation (ECMO) support

    Time frame: Up to 24 months post partum

  7. Number of days in NICU

    Number of days infant was in neonatal intensive care unit

    Time frame: Up to 24 months post partum

  8. Number of days of ventilator support

    Number of reported days infants required ventilator support

    Time frame: Up to 24 months post partum

  9. Number of periventricular leukomalacia at < 2 months postnatally

    Number of infants reported presence of periventricular leukomalacia at \< 2 months postnatally

    Time frame: Up to 2 months post partum

  10. Number of infant complications

    Number of infants reporting the presence of: neonatal sepsis, intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher) or gastro-esophageal reflux

    Time frame: Up to 24 months post partum

  11. Use of patch or muscle flap

    Number of infants reported to require the use of patch or muscle flap

    Time frame: Up to 24 months post partum

  12. Maternal hospitalization

    Number of reported days of maternal hospitalization

    Time frame: Up to 24 months post partum

  13. Route of delivery

    Number of participants that delivered vaginally and via caesarean section

    Time frame: Day 1 (post partum)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2043, 199 months later.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 199 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 27, 2023
StartEst.
Dec 2026
Primary completionEst.
Jul 2043
CompletionEst.
Jul 2043
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05962346
Lead sponsor
Mauro H. Schenone
Responsible party
Mauro H. Schenone (Regulatory Sponsor and Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Jul 27, 2023
Start date
Dec 2026 (estimated)
Primary completion
Jul 2043 (estimated)
Completion
Jul 2043 (estimated)
Last update
Mar 19, 2026

Study contacts

Mauro Schenone, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion